Vincent Mémier

Vincent Mémier

Auto-generated profile, based on publicly available information

Vincent Mémier

Laboratoire d’hématologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CVCaroline Vayne
Caroline Vayne
JRJérôme Rollin
Jérôme Rollin
YGYves Gruel
Yves Gruel
CPClaire Pouplard
Claire Pouplard
HGHubert Galinat
Hubert Galinat
SSSophie Susen
Sophie Susen
In a recent study, Greinacher et al.1 reported thrombotic complications, mostly cerebral vein thrombosis, associated with thrombocytopenia in 11 patients after they had been vaccinated with ChAdOx1 nCoV-19 (AstraZeneca). Although none of these patients had received heparin, the authors detected high titers of anti–platelet factor 4 (PF4)–heparin antibodies that strongly activated platelets in vitro without heparin and in the presence of PF4. This syndrome, which resembles autoimmune heparin-induced thrombocytopenia, was called vaccine-induced immune thrombotic thrombocytopenia (VITT), and an algorithm for the management of this syndrome was proposed on the basis of immunoassays detecting anti–PF4–heparin antibodies.

1 August 2020 in Advances in Biological Regulation
Verified
Journal Article
Closed access
ARAgnès Ribes
Agnès Ribes
FVFanny Vardon-Bounes
Fanny Vardon-Bounes
VMVincent Mémier
Vincent Mémier
MPMichael Poette
Michael Poette
JAJonathan Au-Duong
Jonathan Au-Duong
BPBernard PAYRASTRE
Bernard PAYRASTRE

1 July 2017 in Anesthesiology
Verified
Journal Article
Closed access
PAPierre Albaladejo
Pierre Albaladejo
CSCharles-Marc Samama
Charles-Marc Samama
PSPierre SIE
Pierre SIE
SKSophie Kauffmann
Sophie Kauffmann
VMVincent Mémier
Vincent Mémier
OGon behalf of the GIHP-NACO Study Group
on behalf of the GIHP-NACO Study Group
Background: The use of prothrombin complex concentrates and the role of plasma concentration of anticoagulants in the management of bleeding in patients treated with direct oral anticoagulants are still debated. Our aim was to describe management strategies and outcomes of severe bleeding events in patients treated with direct oral anticoagulants. Methods: We performed a prospective cohort study of 732 patients treated with dabigatran, rivaroxaban, or apixaban hospitalized for severe bleeding, included prospectively in the registry from June 2013 to November 2015. Results: Bleeding was gastrointestinal or intracranial in 37% (212 of 732) and 24% (141 of 732) of the cases, respectively. Creatinine clearance was lower than 60 ml/min in 61% (449 of 732) of the cases. The plasma concentration of direct oral anticoagulants was determined in 62% (452 of 732) of the cases and was lower than 50 ng/ml or higher than 400 ng/ml in 9.2% (41 of 452) and in 6.6% (30 of 452) of the cases, respectively. Activated or nonactivated prothrombin complex concentrates were administered in 38% of the cases (281 of 732). Mortality by day 30 was 14% (95% CI, 11 to 16). Conclusions: Management of severe bleeding in patients treated with direct oral anticoagulants appears to be complex. The use of prothrombin complex concentrates differs depending on bleeding sites and direct oral anticoagulant plasma concentrations. Mortality differs according to bleeding sites and was similar to previous estimates.

10 September 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FVFanny Vardon-Bounes
Fanny Vardon-Bounes
VMVincent Mémier
Vincent Mémier
MMMarina Marcaud
Marina Marcaud
AJAemilia Jacquemin
Aemilia Jacquemin
HHHind Hamzeh-Cognasse
Hind Hamzeh-Cognasse
BPBernard Payrastre
Bernard Payrastre
Sepsis is associated with thrombocytopenia and microvascular thrombosis. Studies have described platelets implication in this pathology but their kinetics of activation and behavior remain poorly known. We show in a mouse model of peritonitis, the appearance of platelet-rich thrombi in organ microvessels and organ damage. Complementary methods are necessary to characterize platelet activation during sepsis as circulating soluble markers and platelet-monocyte aggregates revealed early platelet activation, while surface activation markers were detected at later stage. A microfluidic based ex-vivo thrombosis assay demonstrated that platelets from septic mice have a prothrombotic behavior at shear rate encountered in microvessels. Interestingly, we found that even though phosphoinositide-3-kinase β−deficient platelet mice formed less thrombi in liver microcirculation, peritoneal sepsis activates a platelet alternative pathway to compensate the otherwise mandatory role of this lipid-kinase to form stable thrombi at high shear rate. Platelets are rapidly activated during sepsis. Thrombocytopenia can be attributed in part to platelet-rich thrombi formation in capillaries and platelet-leukocytes interactions. Platelets from septic mice have a prothrombotic phenotype at a shear rate encountered in arterioles. Further studies are necessary to unravel molecular mechanisms leading to this prothrombotic state of platelets in order to guide the development of future treatments of polymicrobial sepsis.

1 March 2014 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
JDJulie DUPOUY
Julie DUPOUY
VMVincent Mémier
Vincent Mémier
HCHélène Catala
Hélène Catala
MLMichel Lavit
Michel Lavit
SOStéphane Oustric
Stéphane Oustric
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre

5 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
CGCédric Garcia
Cédric Garcia
JDJonathan Au Duong
Jonathan Au Duong
MPMichael Poëtte
Michael Poëtte
ARAgnès Ribes
Agnès Ribes
BPBruno Payre
Bruno Payre
FVFanny Vardon-Bounes
Fanny Vardon-Bounes
Mild thrombocytopenia, changes in platelet gene expression, enhanced platelet functionality, and presence of platelet-rich thrombi in the lung have been associated with thromboinflammatory complications of patients with COVID-19. However, whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gets internalized by platelets and directly alters their behavior and function in infected patients remains elusive. Here, we investigated platelet parameters and the presence of viral material in platelets from a prospective cohort of 29 patients with severe COVID-19 admitted to an intensive care unit. A combination of specific assays, tandem mass spectrometry, and flow cytometry indicated high levels of protein and lipid platelet activation markers in the plasma from patients with severe COVID-19 associated with an increase of proinflammatory cytokines and leukocyte-platelets interactions. Platelets were partly desensitized, as shown by a significant reduction of αIIbβ3 activation and granule secretion in response to stimulation and a decrease of surface GPVI, whereas plasma from patients with severe COVID-19 potentiated washed healthy platelet aggregation response. Transmission electron microscopy indicated the presence of SARS-CoV-2 particles in a significant fraction of platelets as confirmed by immunogold labeling and immunofluorescence imaging of Spike and nucleocapsid proteins. Compared with platelets from healthy donors or patients with bacterial sepsis, platelets from patients with severe COVID-19 exhibited enlarged intracellular vesicles and autophagolysosomes. They had large LC3-positive structures and increased levels of LC3II with a co-localization of LC3 and Spike, suggesting that platelets can digest SARS-CoV-2 material by xenophagy in critically ill patients. Altogether, these data show that during severe COVID-19, platelets get activated, become partly desensitized, and develop a selective autophagy response.